Saturday 17 October 2026
Export IMCR’s income statement to Excel — free account
Immunocore Holdings PLC Sponsored ADR
IMCR Healthcare Biotechnology
Immunocore Holdings PLC Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $400.0 million, up 29.0% from fiscal 2024. In the quarter to June 2026, revenue grew 18.3%, EPS grew 92.1%, free cash flow fell 40.7% and total debt was flat, each against the same quarter a year earlier. Revenue growth for three consecutive years.
29.40
0.08
−0.27%
Follow IMCR
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
6 | 3 | 3 | 3 |
| (7.55%) | (9.58%) | (7.14%) | (4.47%) | ||
| (2.67%) | (3.42%) | (2.63%) | (1.64%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(3.39%) | (4.66%) | (3.55%) | (2.18%) | |
Average Days of Receivables |
72.96 | 67.50 | 71.68 | 80.79 | |
Free Cash Flow per Share |
0.06 | (0.30) | (0.61) | (0.81) | |
Free Cash Flow |
2.99 | (15.05) | (30.74) | (41.15) | |
Capital Expenditures |
(5.00) | (4.34) | (5.82) | (6.19) | |
| Other line items | |||||
Cash ROIC |
0.18% | (0.92%) | (1.88%) | (2.43%) | |
Accounts Receivable Turnover |
5.44 | 5.84 | 5.73 | 5.22 | |
Accounts Payable Turnover |
0.13 | 0.21 | 0.16 | 0.19 | |
Inventory Turnover |
0.53 | 0.83 | 0.62 | 0.72 | |
Average Days of Payables |
3,087.30 | 1,748.15 | 2,346.97 | 2,027.53 | |
Days of Inventory on Hand |
760.53 | 483.75 | 642.29 | 600.19 | |
Tax Rate |
0.04 | 0.86 | 1.31 | 5.62 | |
Research and Development Expense of Revenue |
67.68% | 68.71% | 67.71% | 66.03% | |
Selling, General and Administrative Expense of Revenue |
43.49% | 41.35% | 39.50% | 38.11% | |
Share Based Compensation of Revenue |
10.02% | 9.42% | 8.36% | 7.87% | |
Interest Coverage |
(2.79) | (3.73) | (2.83) | (1.85) | |
Operating CF/Net income |
(0.27) | 0.30 | 0.90 | 1.93 | |
Depreciation/Fixed assets |
0.38 | 0.28 | 0.28 | 0.28 | |
Capex/Depreciation |
(1.39) | (1.33) | (1.73) | (1.72) | |
Revenue per Share |
7.53 | 7.95 | 8.13 | 8.45 | |
Operating CF per Share |
0.16 | (0.21) | (0.49) | (0.69) | |
Capex per Share |
(0.10) | (0.09) | (0.11) | (0.12) | |
Capex to Sales |
0.01 | 0.01 | 0.01 | 0.01 |
Columns are period end dates